Gomekli (mirdametinib) is the first treatment that is FDA approved for both adults and children with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas (PN). Selumetinib (Koselugo), a ...
GOMEKLI is the first FDA-approved treatment for adult and pediatric NF1-PN, showing effective tumor reduction and manageable safety. SpringWorks Therapeutics has announced the FDA approval of GOMEKLI ...
CNW/ - Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib), an oral, selective MEK inhibitor, has been approved in ...
Holly Griffin loves running for the journey, but she also keeps the finish line in mind. Griffin and her son Hayes have a genetic condition called neurofibromatosis. She's raised about $30K through ...
CAMBRIDGE, England--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company dedicated to rare diseases, today announced the first patient has been dosed in INSPIRE-NF1, a Phase 2 trial ...
NFX funds scientific and medical research that aims to advance treatment options for NF. (NFX) DETROIT – The Detroit nonprofit NF Forward, which aims to accelerate treatments and cures for ...
RECKGIST score effectively predicts recurrence in neurofibromatosis type 1-associated GISTs, especially for tumors under 30 mm. Larger GISTs (over 30 mm) have a higher risk of metastasis, with ...
Panelists discuss the unmet needs in NF1-associated plexiform neurofibromas, highlighting gaps in effective treatment, pain management, psychosocial support, and prevention of malignant transformation ...
PITTSBURGH, April 16, 2025 /PRNewswire/ -- The Giorgio Foundation and the University of Pittsburgh announce the establishment of The Giorgio Foundation Endowed Chair in the School of Medicine's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results